161 related articles for article (PubMed ID: 34038868)
21. CXCR2/CXCL5 axis contributes to epithelial-mesenchymal transition of HCC cells through activating PI3K/Akt/GSK-3β/Snail signaling.
Zhou SL; Zhou ZJ; Hu ZQ; Li X; Huang XW; Wang Z; Fan J; Dai Z; Zhou J
Cancer Lett; 2015 Mar; 358(2):124-135. PubMed ID: 25462858
[TBL] [Abstract][Full Text] [Related]
22. PCNA-associated factor P15
Jin C; Liu Z; Li Y; Bu H; Wang Y; Xu Y; Qiu C; Yan S; Yuan C; Li R; Diao N; Zhang Z; Wang X; Liu L; Kong B
Int J Cancer; 2018 Dec; 143(11):2973-2984. PubMed ID: 30129654
[TBL] [Abstract][Full Text] [Related]
23. MicroRNA-302 represses epithelial-mesenchymal transition and cisplatin resistance by regulating ATAD2 in ovarian carcinoma.
Ge T; Liu T; Guo L; Chen Z; Lou G
Exp Cell Res; 2020 Nov; 396(1):112241. PubMed ID: 32835657
[TBL] [Abstract][Full Text] [Related]
24. Bisdemethoxycurcumin sensitizes cisplatin-resistant lung cancer cells to chemotherapy by inhibition of CA916798 and PI3K/AKT signaling.
Wang HJ; Yang ZX; Dai XT; Chen YF; Yang HP; Zhou XD
Apoptosis; 2017 Sep; 22(9):1157-1168. PubMed ID: 28677094
[TBL] [Abstract][Full Text] [Related]
25. Rebound increases in chemokines by CXCR2 antagonist in breast cancer can be prevented by PKCδ and PKCε activators.
Erin N; Tavşan E; Akdeniz Ö; Isca VMS; Rijo P
Cytokine; 2021 Jun; 142():155498. PubMed ID: 33773907
[TBL] [Abstract][Full Text] [Related]
26. A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer.
Choi HJ; Heo JH; Park JY; Jeong JY; Cho HJ; Park KS; Kim SH; Moon YW; Kim JS; An HJ
Gynecol Oncol; 2019 Apr; 153(1):135-148. PubMed ID: 30686552
[TBL] [Abstract][Full Text] [Related]
27. CXCL2/CXCR2 axis induces cancer stem cell characteristics in CPT-11-resistant LoVo colon cancer cells via Gαi-2 and Gαq/11.
Chen MC; Baskaran R; Lee NH; Hsu HH; Ho TJ; Tu CC; Lin YM; Viswanadha VP; Kuo WW; Huang CY
J Cell Physiol; 2019 Jul; 234(7):11822-11834. PubMed ID: 30552676
[TBL] [Abstract][Full Text] [Related]
28. MiR-1294 confers cisplatin resistance in ovarian Cancer cells by targeting IGF1R.
Zhang Y; Huang S; Guo Y; Li L
Biomed Pharmacother; 2018 Oct; 106():1357-1363. PubMed ID: 30119207
[TBL] [Abstract][Full Text] [Related]
29. The Clinicopathological Significance of the CXCR2 Ligands, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, and CXCL8 in Gastric Cancer.
Yamamoto Y; Kuroda K; Sera T; Sugimoto A; Kushiyama S; Nishimura S; Togano S; Okuno T; Yoshii M; Tamura T; Toyokawa T; Tanaka H; Muguruma K; Ohira M; Yashiro M
Anticancer Res; 2019 Dec; 39(12):6645-6652. PubMed ID: 31810929
[TBL] [Abstract][Full Text] [Related]
30. Effects of microRNA-1271 on ovarian cancer via inhibition of epithelial-mesenchymal transition and cisplatin resistance.
Chen Y; Wang L; Zhou J
J Obstet Gynaecol Res; 2019 Nov; 45(11):2243-2254. PubMed ID: 31411791
[TBL] [Abstract][Full Text] [Related]
31. PD98059 impairs the cisplatin-resistance of ovarian cancer cells by suppressing ERK pathway and epithelial mesenchymal transition process.
Hou L; Hou X; Wang L; Li Z; Xin B; Chen J; Gao X; Mu H
Cancer Biomark; 2017 Dec; 21(1):187-194. PubMed ID: 29103028
[TBL] [Abstract][Full Text] [Related]
32. The role of interleukin-8 (IL-8) and IL-8 receptors in platinum response in high grade serous ovarian carcinoma.
Stronach EA; Cunnea P; Turner C; Guney T; Aiyappa R; Jeyapalan S; de Sousa CH; Browne A; Magdy N; Studd JB; Sriraksa R; Gabra H; El-Bahrawy M
Oncotarget; 2015 Oct; 6(31):31593-603. PubMed ID: 26267317
[TBL] [Abstract][Full Text] [Related]
33. Preclinical Efficacy for AKT Targeting in Clear Cell Carcinoma of the Ovary.
Sasano T; Mabuchi S; Kuroda H; Kawano M; Matsumoto Y; Takahashi R; Hisamatsu T; Sawada K; Hashimoto K; Isobe A; Testa JR; Kimura T
Mol Cancer Res; 2015 Apr; 13(4):795-806. PubMed ID: 25519148
[TBL] [Abstract][Full Text] [Related]
34. Atezolizumab and Bevacizumab Attenuate Cisplatin Resistant Ovarian Cancer Cells Progression Synergistically via Suppressing Epithelial-Mesenchymal Transition.
Zhang L; Chen Y; Li F; Bao L; Liu W
Front Immunol; 2019; 10():867. PubMed ID: 31105696
[TBL] [Abstract][Full Text] [Related]
35. Snail promotes ovarian cancer progression by recruiting myeloid-derived suppressor cells via CXCR2 ligand upregulation.
Taki M; Abiko K; Baba T; Hamanishi J; Yamaguchi K; Murakami R; Yamanoi K; Horikawa N; Hosoe Y; Nakamura E; Sugiyama A; Mandai M; Konishi I; Matsumura N
Nat Commun; 2018 Apr; 9(1):1685. PubMed ID: 29703902
[TBL] [Abstract][Full Text] [Related]
36. Hexokinase 2 confers resistance to cisplatin in ovarian cancer cells by enhancing cisplatin-induced autophagy.
Zhang XY; Zhang M; Cong Q; Zhang MX; Zhang MY; Lu YY; Xu CJ
Int J Biochem Cell Biol; 2018 Feb; 95():9-16. PubMed ID: 29247711
[TBL] [Abstract][Full Text] [Related]
37. Tubeimoside I sensitizes cisplatin in cisplatin-resistant human ovarian cancer cells (A2780/DDP) through down-regulation of ERK and up-regulation of p38 signaling pathways.
Liu HZ; Yu C; Yang Z; He JL; Chen WJ; Yin J; Li WM; Liu HT; Wang YX
Mol Med Rep; 2011; 4(5):985-92. PubMed ID: 21687949
[TBL] [Abstract][Full Text] [Related]
38. GRO-α and IL-8 enhance ovarian cancer metastatic potential via the CXCR2-mediated TAK1/NFκB signaling cascade.
Yung MM; Tang HW; Cai PC; Leung TH; Ngu SF; Chan KK; Xu D; Yang H; Ngan HY; Chan DW
Theranostics; 2018; 8(5):1270-1285. PubMed ID: 29507619
[TBL] [Abstract][Full Text] [Related]
39. JNK- and Akt-mediated Puma expression in the apoptosis of cisplatin-resistant ovarian cancer cells.
Zhao Z; Wang J; Tang J; Liu X; Zhong Q; Wang F; Hu W; Yuan Z; Nie C; Wei Y
Biochem J; 2012 Jun; 444(2):291-301. PubMed ID: 22394200
[TBL] [Abstract][Full Text] [Related]
40. Aspirin enhances cisplatin sensitivity of resistant non-small cell lung carcinoma stem-like cells by targeting mTOR-Akt axis to repress migration.
Khan P; Bhattacharya A; Sengupta D; Banerjee S; Adhikary A; Das T
Sci Rep; 2019 Nov; 9(1):16913. PubMed ID: 31729456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
